Frontlight ResearchEarly access
Active, not recruitingNo phase
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
Key facts
- Who runs it
- Rocket Pharmaceuticals Inc.
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 9 people, planned
- Started
- 1 Jun 2020
- Expected to end
- 17 Jan 2034
- Type of study
- Observational
- Treatments tested
- Safety and efficacy assessments
- Record updated
- 13 April 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Enrolled in the FANCOLEN-I study
- Treated with gene therapy in the FANCOLEN-I study
- Able to adhere to the study visit schedule and protocol requirements
- Provided written informed consent and, as applicable, assent to participate
Who cannot take part
- There are no exclusion criteria for this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a long-term safety and efficacy follow-up study for subjects with Fanconi Anaemia Subtype A who have been treated with ex vivo gene therapy on the FANCOLEN-I trial. After completion of the FANCOLEN-I study, eligible subjects will be followed for a total of 15 years post gene therapy treatment. No investigational drug product will be administered during this study.
The group in the trial
- Subjects with Fanconi Anaemia Subtype A (FA-A)
Subjects treated with ex vivo lentiviral gene therapy product in FANCOLEN-I trial and agree to participate in this long-term follow-up (LTFU) study
Treatment: Safety and efficacy assessments
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene in Patients With Fanconi Anaemia Subtype A: FANCOLEN-I
- Publications
- Record updated
- 13 April 2026